California Institute of Technology

Dsm Fine Chemicals Austria Nfg Gmbh & Co. Kg

Technische Universitat Graz

Vtu Holding Gmbh

Bisy E.u.

Bisy Gmbh

Dsm IP Assets B.v.

Clariant Produkte (deutschland) Gmbh

Biocatalytics, Inc.

Acib Gmbh

Anton Glieder

Frances H Arnold

Ulrich Schwaneberg

Edgardo Farinas

Wolfgang Skranc

Thomas Vogl

Helmut Schwab

Herbert Mayrhofer

Irma Wirth

Rudolf Neuhofer

Peter Pöchlauer

Christoph Kratky

Franz Hartner

Ingrid Dreveny

Rodolfo Bona

Christoph Reisinger

Isabel Unterstrasser

Christian Gamauf

Michael Kraus

Aleksandra Mitrovic

Karl Gruber

Grit Straganz

Kay Domenico Novak

Astrid Weninger

Carsten Pichler

Richard Wasmayer

Pia Fauland

Lothar Brecker

Lukas Sturmberger

Martina Geier

Claudia Rinnofner

Richard Gaisberger

Zhibin Liu

Beate Pscheidt

Roland Weis

Ruud Luiten

Thomas Kickenweiz

Richard Gaissberger

The invention relates to polypeptides having peroxygenase activity and compositions comprising such polypeptides. The invention also relates to improved methods of producing such polypeptides in yeasts.

Recombinant heme thiolate oxygenases

The present invention relates to a yeast cell of thegenus comprising an orthologous promoter of a methylotrophic yeast cell or a variant thereof inducible by derepression, wherein the orthologous promoter is an orthologous formate dehydrogenase (FMD) promoter of a methylotrophic yeast cell.

Yeast cell

An episomal plasmid comprising a gene of interest (GOI) and an autonomously replicating sequence (ARS) which is not operably linked to the GOI, which ARS comprises or consists of a nucleotide sequence identified as any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6-11, or a functionally active variant of any of the foregoing which is characterized by at least 60% sequence identity thereto.

Episomal plasmid vectors

The present invention relates to an optimized metabolic pathway design in. In particular, to a recombinant polycistronic expression construct for stable expression of multiple genes of interest in a yeast cell, preferably in

Compact and optimized metabolic pathway design in

The present application provides novel polypeptides having xylanase activity and the respective nucleic acid sequences encoding those polypeptides as well as vectors comprising these nucleic acid sequences and host cells transformed by these vectors. In addition the present invention provides a method for producing these polypeptides and a composition comprising the inventive polypeptides.

Polypeptides having xylanase activity with a high conversion rate of xylose&#x2014;containing polysaccharides

The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectionalor CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising

Bidirectional promoter

Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.

Cytochrome P450 oxygenases

A mutantalcohol oxidase 1 (AOX1) promoter of the wild typeAOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (&#x2212;784 to &#x2212;719), nucleotides 170 to 191 (&#x2212;784 to &#x2212;763), nucleotides 192 to 213 (&#x2212;762 to &#x2212;741), nucleotides 192 to 210 (&#x2212;762 to &#x2212;744), nucleotides 207 to 209 (&#x2212;747 to &#x2212;745), nucleotides 214 to 235 (&#x2212;740 to &#x2212;719), nucleotides 304 to 350 (&#x2212;650 to &#x2212;604), nucleotides 364 to 393 (&#x2212;590 to &#x2212;561), nucleotides 434 to 508 (&#x2212;520 to &#x2212;446), nucleotides 509 to 551 (&#x2212;445 to &#x2212;403), nucleotides 552 to 560 (&#x2212;402 to &#x2212;394), nucleotides 585 to 617 (&#x2212;369 to &#x2212;337), nucleotides 621 to 660 (&#x2212;333 to &#x2212;294), nucleotides 625 to 683 (&#x2212;329 to &#x2212;271), nucleotides 736 to 741 (&#x2212;218 to &#x2212;213), nucleotides 737 to 738 (&#x2212;217 to &#x2212;216), nucleotides 726 to 755 (&#x2212;228 to &#x2212;199), nucleotides 784 to 800 (&#x2212;170 to &#x2212;154) or nucleotides 823 to 861 (&#x2212;131 to &#x2212;93) of Seq ID No. 1, and combinations thereof.

Mutant AOX1 promoters

The invention relates to R-hydroxynitrile lyases with improved substrate acceptance, increased activity and increased selectivity, obtainable by introducing random mutations with the aid of random mutagenesis and/or saturation mutagenesis techniques, identifying by means of screening or selection and, where appropriate, subsequently combining advantageous mutations, and to the use thereof.

[object Object]

The invention relates to R-hydroxynitrillyases from the family of Rosaceae that are characterized by an improved substrate tolerance and increased stability. In the active center of the R-hydroxynitrillyases either a) an alanine group is substituted by glycine, valine, leucine, isoleucine, or phenylalanine or b) a phenylalanine group is substituted by alanine, glycine valine, leucine or isoleucine, or c) a leucine group is substituted by alanine, glycine, valine, isoleucine or phenylalanine, or d) an isoleucine group is substituted by alanine, glycine, valine, leucine or phenylalanine. The invention also relates to the use of these lyases in the production of enantiomer-pure R- or S-cyanohydrines.

Growing community of inventors

Gleisdorf, Austria

Anton Glieder